- Shanghai Pharma reported earnings per share (EPS) of 36 RMB cents for the first quarter.
- This EPS figure was below the market estimate of 42 RMB cents, based on two estimates.
- The company reported a net income of 1.33 billion yuan for the quarter.
- Operating revenue for the quarter was 70.76 billion yuan.
- Analyst recommendations include 9 buys, 2 holds, and 1 sell.
A look at Shanghai Pharmaceuticals Holding Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shanghai Pharmaceuticals Holding Co., Ltd, a company that manufactures pharmaceuticals in China, has shown strong potential according to the Smartkarma Smart Scores. With a top score in the Value category and a solid score in dividends, the company appears to be a strong contender in the market. While its Growth score is not the highest, Shanghai Pharmaceuticals Holding still demonstrates resilience and manages to maintain a steady momentum in its operations.
Looking ahead, the long-term outlook for Shanghai Pharmaceuticals Holding seems promising, considering its impressive scores in value and dividends. These scores indicate that the company is well-positioned for growth and stability in the pharmaceutical industry. With a focus on developing and selling a range of medications and healthcare products, Shanghai Pharmaceuticals Holding aims to continue its success in the Chinese market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
